Warning letter
TAKA USA, INC. dba Cosmetic Innovations: warning letter of Jul 29, 2020
FDA warning letter 587521 · Division of Pharmaceutical Quality Operations II
Key facts
| Reference number | 587521 |
|---|---|
| Company | TAKA USA, INC. dba Cosmetic Innovations |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Jul 29, 2020 |
| Posted date | Aug 11, 2020 |
| Issuing office | Division of Pharmaceutical Quality Operations II |
| Product type | Drugs |
| CFR sections cited | 211.34, 211.84(d)(1), 211.100(a), 211.165(a), 211.166(a) |
| Inspection city | Coppell |
| Inspection ZIP | 75019 |
| Inspection start date | Jun 3, 2019 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: